Recent studies of GLP-1 agonists among obese individuals with or without T2DM lasting over 1 year demonstrate encouraging adherence rates, though the individuals have extensive support while on study and may not accurately reflect real-world findings. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.